Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
Histologically confirmed adenocarcinoma of the prostate
Prostate adenocarcinoma (PAC)
Histologically confirmed prostate adenocarcinoma within 365 days prior to randomization.
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed prostate adenocarcinoma
Histologically confirmed prostate adenocarcinoma
Histologically-confirmed adenocarcinoma of the prostate
Histologically documented adenocarcinoma prostate cancer confirmed by a pathology report from prostate biopsy or a radical prostatectomy specimen; if prostatic tumor is of mixed histology, > 50% of the tumor must be adenocarcinoma
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed prostate adenocarcinoma at the time of surgery
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate, who meet the following criteria:
Histologically confirmed adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Documented histologically confirmed adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Histologically-confirmed adenocarcinoma of the prostate
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed prostate adenocarcinoma
Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12 core prostate biopsy completed within 1-year of enrollment (note: most recent prostate biopsy must have demonstrated prostatic adenocarcinoma)
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed prostate cancer
Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
Histologically confirmed diagnosis of adenocarcinoma of the prostate and most recent biopsy within 365 days of study enrollment
Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate from a prostate biopsy or prostatectomy specimen (primary site), or histological confirmation of adenocarcinoma/carcinoma in a metastatic site of disease in the setting of elevated prostate specific antigen (PSA) and imaging consistent with metastatic prostate cancer, or history of prostate cancer with documented metastasis, or histologically confirmed other solid tumor malignancy, multiple myeloma, or plasmacytoma with pathological confirmation of metastasis
Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate
Histologically-confirmed adenocarcinoma of the prostate
All patients must have histologically confirmed prostate adenocarcinoma, with biopsies obtained within twelve months of patient registration
Histologically confirmed prostate adenocarcinoma within 365 days of registration
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Diagnosis of prostate adenocarcinoma as confirmed by the investigator
Histologically confirmed prostate cancer (not exclusive of adenocarcinoma)
Males with histologically confirmed adenocarcinoma of the prostate
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Subjects must have biopsy-confirmed adenocarcinoma of the prostate
Pathologically confirmed diagnosis of prostate adenocarcinoma
Histologically confirmed adenocarcinoma of the prostate (biopsy within one year of enrollment)
Histologically confirmed adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Histologically confirmed, castrate-resistant adenocarcinoma of the prostate
Histologically confirmed, locally confined adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Diagnosis of prostate adenocarcinoma as confirmed by the investigator
Histologically confirmed, localized adenocarcinoma of the prostate
Biopsy confirmed adenocarcinoma of the prostate, performed up to 6 months prior to scheduled treatment.
Adenocarcinoma of the prostate
The patient has pathologically confirmed adenocarcinoma of the prostate
Histologically documented adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
COHORT A: The subject must have histologically confirmed adenocarcinoma of the prostate with tissue confirmation at selected study site
Subject has histologically confirmed metastatic adenocarcinoma of the prostate.
Patients must have histologically confirmed adenocarcinoma of the prostate gland
Histologically confirmed adenocarcinoma of the prostate
Participants must have histologically confirmed prostate cancer.
Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)
Histologically confirmed adenocarcinoma of the prostate with metastatic disease.
Histologically confirmed adenocarcinoma of the prostate.
Adenocarcinoma of the Prostate
Documented histologically confirmed adenocarcinoma of the prostate
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Documented histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Adenocarcinoma of the prostate
Confirmed metastatic adenocarcinoma of the prostate that is unresponsive or refractory to hormonal therapy
Histologically-confirmed adenocarcinoma of the prostate
Histologically-documented localized (stage < T3) prostate adenocarcinoma
History of histologically confirmed prostate cancer
Histologically confirmed adenocarcinoma of the prostate.
Histologically confirmed prostate cancer
Histologically confirmed adenocarcinoma of the prostate
Histologically confirmed adenocarcinoma of the prostate
Biopsy confirmed adenocarcinoma of the prostate within 18 months prior to enrollment
Histologically-confirmed prostate cancer
Patients with histologically confirmed prostate cancer
Histologically confirmed primary adenocarcinoma of the prostate
Participants must have histologically confirmed prostate cancer
Histologically confirmed adenocarcinoma of the prostate
Patients with histologically confirmed prostate cancer
